Rubber stoppered glass vial systems are widely used as primary containers for storing and delivering therapeutic protein products to patients. Addressing concerns and regulatory expectations related to the risk to biologic drug product quality and patient safety from rubber stoppered glass vial systems requires implementation of an extractable and leachable evaluation program based on material understanding, risk assessment, literature review, and a comprehensive scientifically sound analytical testing methodology. The extractable and leachable study design consisted of twelve drug products filled in twelve different size glass vials capped with laminated and nonlaminated rubber stoppers made from three different rubber formulations. Design of the model solvents was successful as they had little to no analytical interference and mimicked the formulation conditions and generated representative extractables capable of predicting leachables. The extraction conditions of time and temperature were appropriate as not to degrade the test materials or the extractable compounds, and yet generated significant quantities for identification of the extractable compounds with confidence. The extractables testing results were capable of predicting the leachable profiles of the twelve drug products. In each case, the leachable profile was a subset of the extractable profile. The organic and elemental impurities of the leachable profiles of drug products were the end-to-end verification of the quality of the glass vials, rubber stoppers and drug product lifecycles. Overall, the holistic approach was fully successful in the qualification of different vial systems as primary containers and delivery systems for different biotherapeutic products to ensure product quality and patient safety.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.xphs.2021.07.015DOI Listing

Publication Analysis

Top Keywords

vial systems
16
rubber stoppered
12
stoppered glass
12
glass vial
12
drug products
12
holistic approach
8
systems primary
8
primary containers
8
drug product
8
product quality
8

Similar Publications

Distinguishing abiotic corrosion from two types of microbiologically influenced corrosion (MIC) using a new electrochemical biofilm/MIC test kit.

J Environ Manage

January 2025

Department of Chemical & Biomolecular Engineering, Institute for Corrosion and Multiphase Technology, Ohio University, Athens, 45701, USA; Department of Biological Sciences, Molecular & Cellular Biology Program, Ohio University, Athens, OH, 45701, USA. Electronic address:

Biofilms can cause biofouling, water quality deterioration, and transmission of infectious diseases. They are also responsible for microbiologically influenced corrosion (MIC) which can cause leaks, resulting in environmental disasters. A new disposable biofilm/MIC test kit was demonstrated to distinguish abiotic corrosion of carbon steel from MIC.

View Article and Find Full Text PDF

Protein aggregation in the frozen state induced by dropping stress.

Eur J Pharm Sci

February 2025

Department of Biotechnology, Graduate School of Engineering, Osaka University, 2-1 Yamadaoka, Suita, Osaka 565-0871, Japan; Exploratory Research Center on Life and Living Systems, National Institutes of Natural Sciences, 5-1 Higashiyama, Myodaiji, Okazaki, Aichi 444-8787, Japan. Electronic address:

The formation of protein aggregates, which can be immunogenic and lower the efficacy and safety of protein drugs, has been an issue in biopharmaceutical development for more than a decade. Although protein drugs are often shipped as frozen material, the effect of the accidental dropping of frozen proteins, which can occur during shipping and handling, on the physical stability has not been studied. Here, a frozen Fc fusion protein was subjected to dropping stress and the increase in the aggregate concentration was evaluated.

View Article and Find Full Text PDF

Recent developments in treatments for both forms of advanced age-related macular degeneration (AMD) have led to the approval of multiple agents and modalities within the last few years. Five new medications for both neovascular AMD (nAMD) and geographic atrophy (GA) secondary to nonexudative AMD (neAMD) have been FDA-approved within the last 5 years, along with a new device designed for sustained drug delivery for nAMD. In nAMD, the newest agents approved by the FDA are brolucizumab (Novartis Pharmaceuticals, Basel, Switzerland), faricimab (F.

View Article and Find Full Text PDF
Article Synopsis
  • Longer periods between headache episodes may allow the nervous system to recover better, possibly enhancing patients' quality of life and disease status.
  • The study, PROMISE-2, analyzed data from over 1,000 chronic migraine patients to examine the relationship between the length of interictal periods (time between headaches) and various patient-reported health outcomes.
  • Results showed that patients with interictal periods longer than 21 days reported significantly better improvements in headache impact, overall health status, and bothersome symptoms compared to those with shorter periods.
View Article and Find Full Text PDF

Introduction: The purpose of this study was to assess and compare the effectiveness of seven different closed system transfer device (CSTD) product lines following the 2015 NIOSH Vapor Containment Performance Protocol, using a Gasmetâ„¢ DX5000 Terra multigas FTIR analyzer.

Methods: Seven different CSTD systems were assessed using a two-task evaluation on their capacity to contain the NIOSH-specified challenge agent, 70% isopropyl alcohol (IPA). Task 1 simulated reconstitution and compounding steps while Task 2 simulated compounding and administration steps.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!